Use of EGFR inhibitors in the preparation of drugs for treating breast cancer
By developing the compound of formula I as an EGFR-TKI inhibitor, inhibiting the EGFR/PI3K/AKT signaling pathway, the targeting problem in the treatment of triple-negative breast cancer was solved, and the proliferation inhibition and apoptosis of MDA-MB-231 cells was achieved. Induction, provides new therapeutic strategies and enhances drug sensitivity.
Patent Information
- Application Number
- CN202110544920.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-05-19
- Filing Date
- 2021-05-19
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2041-05-19
AI Technical Summary
Triple-negative breast cancer lacks effective drug targets and therapeutic methods. The existing application of EGFR-TKI in breast cancer treatment has not been fully studied, and chemotherapy resistance and adverse reactions are the main challenges.
Develop an EGFR-TKI inhibitor called Formula I, inhibits the proliferation of triple-negative breast cancer cells by inhibiting the EGFR/PI3K/AKT signaling pathway, induces cell autophagy and apoptosis, and discusses its in breast cancer, especially triads Treatment effects in negative breast cancer.
The compounds of formula I showed significant anti-tumor effects, and had good proliferation inhibition and inducing apoptosis effects on MDA-MB-231 cells of triple-negative breast cancer, providing new theoretical and experimental basis for the treatment of triple-negative breast cancer. And combined with autophagy inhibitors can enhance cell sensitivity to drugs.
Smart Images

Figure CN113679723B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the fields of clinical medicine and pharmaceuticals; specifically, it relates to the use of epidermal growth factor receptor tyrosine kinase inhibitors in the preparation of drugs for treating breast cancer. Background Art
[0002] Breast cancer is the leading cause of cancer-related death in women worldwide, and its incidence and mortality rate ranked second in global cancer statistics in 2018. With the deepening of understanding of breast cancer, the treatment of breast cancer has entered the era of comprehensive treatment. Molecular targeted therapy is one of the hot topics in breast cancer research in recent years. Compared with chemotherapy drugs, it is a new anti-tumor drug with multiple mechanisms of action. However, triple-negative breast cancer (TNBC), as a type of breast cancer, accounts for 10%-20% of all breast cancers. Compared with other types of breast cancer, it has the characteristics of strong invasiveness, lack of effective drug targets and single clinical treatment methods. Therefore, it is urgent to find new and effective drugs and therapeutic targets. In the past few years, potential TNBC therapeutic targets have been discovered by targeting different signal pathways, such as epidermal growth factor receptor (EGFR). EGFR is a receptor for epidermal growth factor involved in cell proliferation and signal transduction. Studies have shown that EGFR exhibits abnormalities in a variety of human tumors, including gene amplification and mutation, and is highly expressed in nearly 80% of tumor cells.
[0003] Studies have shown that EGFR-TKI can exert anti-tumor effects on a variety of cancers, such as lung cancer, breast cancer, etc. EGFR-TKI inhibits the formation of EGFR dimers by blocking the autophosphorylation of tyrosine in the EGFR molecule and the activation of tyrosine kinase, thereby inhibiting EGFR activation, preventing downstream signal transduction, inhibiting cell cycle progression, inducing cell autophagy and accelerating cell apoptosis. The compound of formula I is a small molecule anti-tumor compound with independent intellectual property rights, which can target EGFR to exert anti-tumor activity and belongs to EGFR-TKI:
[0004]
[0005] It is clear that the compound of formula I can be used to treat advanced non-small cell lung cancer, but its therapeutic effect in breast cancer, especially triple-negative breast cancer, has not been studied. Therefore, this study uses the new EGFR-TKI inhibitor as the research object to observe its inhibitory effect on the proliferation of TNBC MDA-MB-231 cells and its effect on cell apoptosis and autophagy, and explores the relevant possible mechanisms to provide new theoretical and experimental basis for opening up clinical treatment approaches for TNBC. For many years, chemotherapy has been the main systemic treatment option for TNBC to improve the overall survival rate of patients, but chemotherapy resistance and adverse reactions are many challenges faced by TNBC patients in the treatment. Therefore, many studies have detected molecular changes before and after chemotherapy to determine possible targeted treatments for TNBC and provide new solutions for disease treatment. In this study, we found that the compound of formula I has a good anti-tumor effect on TNBC in vitro. Although triple-negative breast cancer MDA-MB-231 cells do not express receptors such as ER, PR, and HER2, they express EGFR. The results of this study show that the compound of formula I, as an EGFR-TKI, can effectively inhibit the growth and proliferation of MDA-MB-231 cells and induce cell autophagy and apoptosis.
[0006] The research results of the present invention show that the compound of formula I can inhibit the proliferation of TNBC MDA-MB-231 cells by inhibiting the EGFR / PI3K / AKT signaling pathway, induce cell autophagy and apoptosis, and has an anti-tumor effect, providing experimental basis for the possibility that targeting EGFR may become an effective treatment strategy for TNBC. At the same time, combining with autophagy inhibitors to enhance the sensitivity of cells to drugs may be a feasible additional approach. Summary of the invention
[0007] The inventors surprisingly found that the compound of formula I or a pharmaceutically acceptable salt thereof has a good therapeutic effect on breast cancer, especially triple-negative breast cancer.
[0008] One aspect of the present invention is to provide a use of a compound of formula I or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating breast cancer.
[0009]
[0010] Wherein, the pharmaceutically acceptable salt is selected from one or a combination of the following: methanesulfonate, fumarate, maleate, acetate, hydrochloride, phosphate or sulfate.
[0011] In a further preferred embodiment of the present invention, the breast cancer is triple-negative breast cancer.
[0012] In a further preferred embodiment of the present invention, the triple-negative breast cancer refers to: when semi-quantitative immunohistochemistry analysis is performed using a polyclonal anti-HER2 primary antibody, the cancer cells are negative for estrogen receptor (ER) and progesterone receptor and produce test results of 0, 1+ or 2+.
[0013] In a further preferred embodiment of the present invention, the cancer cells are FISH negative for HER2 gene amplification.
[0014] In a further preferred embodiment of the present invention, the triple-negative breast cancer is HER3+ or FISH-positive breast cancer.
[0015] In a further preferred embodiment of the present invention, the triple-negative breast cancer is histopathologically characterized by a basal-like phenotype.
[0016] In a further preferred embodiment of the present invention, the breast cancer is accompanied by mutations in one or more genes among BRCA1, BRCA2, PALB2, FANCM or TP53.
[0017] In a further preferred embodiment of the present invention, the breast cancer is advanced breast cancer with liver metastasis, lung metastasis, lymph node metastasis or bone metastasis.
[0018] In a further preferred embodiment of the present invention, the baseline plasma concentration of sMET in breast cancer patients is greater than or equal to a median of 795 mg / ml.
[0019] In a further preferred embodiment of the present invention, the compound of formula I or a pharmaceutically acceptable salt thereof plays a role in treating breast cancer by inhibiting the EGFR / PI3K / AKT signaling pathway.
[0020] In a further preferred embodiment of the present invention, the pharmaceutically acceptable salt is selected from methanesulfonate.
[0021] In a further preferred embodiment of the present invention, the medicament optionally further comprises a pharmaceutically acceptable carrier, diluent or excipient.
[0022] The unit dose of the compound of formula I or a pharmaceutically acceptable salt thereof (for example, but not limited to, daily unit dose) is 50 mg to 300 mg (including ±10%) of the compound of formula I, for example, but not limited to 45, 46, 47, 48, 49, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180 0, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260, 265, 270, 275, 280, 285, 290, 295, 300, 310, 320, 330 mg, and values between any two of the above values (although not listed one by one, but deemed to be clearly indicated); more specifically, it can be 55 mg, 110 mg, 220 mg or 260 mg. It can be prepared into a unit dosage form of the corresponding daily dosage, administered once a day, and the patient should avoid eating within 1 hour before administration to 2 hours after administration.
[0023] The medicaments prepared from the compounds of formula I or their pharmaceutically acceptable salts are suitable for oral administration.
[0024] In a further preferred embodiment of the present invention, the compound of formula I or a pharmaceutically acceptable salt thereof is administered alone, that is, it does not need to be used in combination with other drugs having anti-tumor effects, but the use of some auxiliary drugs without anti-tumor effects is not excluded.
[0025] In a further preferred embodiment of the present invention, the compound of formula I or a pharmaceutically acceptable salt thereof can be used in combination with other drugs for treating breast cancer or autophagy-related inhibitors, wherein other drugs for treating breast cancer or autophagy-related inhibitors include chloroquine, taxanes, platinum drugs, tyrosine kinase inhibitors or monoclonal antibodies.
[0026] Another object of the present invention is to provide a method for treating breast cancer, especially triple-negative breast cancer, comprising the steps of:
[0027] Provide a compound represented by formula I or a pharmaceutically acceptable salt thereof
[0028]
[0029] Administering a compound of Formula I or a pharmaceutically acceptable salt thereof to a subject in a therapeutically effective amount;
[0030] The subject suffers from breast cancer; in particular triple-negative breast cancer.
[0031] In some embodiments, the route of administration is selected from the group consisting of: intramuscular, intraperitoneal, intravenous, subcutaneous, transdermal, intradermal, intranasal, intraocular, oral, sublingual, intratumoral, peritumoral.
[0032] In some embodiments, the method of treatment administers the composition to the patient at a frequency selected from the following: 3 times in two months, 4 times in two months, 5 times in two months, 2 times a month, once in three weeks, twice in three weeks, once a week, twice a week, 3 times a week, 4 times a week, 5 times a week, 6 times a week, 7 times a week, once a day, once every two days, twice a day, and a unit dose of 3 times a day. BRIEF DESCRIPTION OF THE DRAWINGS
[0033] Figure 1 The CCK8 test of the compound of formula I on the survival rate of MDA-MB-231 cells;
[0034] Figure 2 Represents the experiment of the compound of formula I on the clone formation of MDA-MB-231 cells;
[0035] Figure 3 The effect of the compound of formula I on the morphology of MDA-MB-231 cells;
[0036] Figure 4-5 The flow cytometry experiment of the compound of formula I on apoptosis of MDA-MB-231 cells is shown;
[0037] Figure 6-7 It represents the Western blot test results of the compound of formula I on the expression of apoptosis-related proteins in MDA-MB-231 cells;
[0038] Figure 8 The results of the autophagy test of the compound of formula I on MDA-MB-231 cells are shown;
[0039] Figure 9-10 It represents the Western blot test results of the compound of formula I on the expression of autophagy-related proteins in MDA-MB-231 cells;
[0040] Fig.11 The CCK8 test of the effect of the compound of formula I and CQ alone or in combination on the survival rate of MDA-MB-231 cells is shown;
[0041] Figure 12-13 It represents the Western blot detection results of the expression of autophagy-related proteins in MDA-MB-231 cells using the compound of formula I and CQ alone or in combination;
[0042] Figure 14-16The results of Western blot analysis of the compound of formula I on the expression of proteins related to the EGFR / PI3K / AKT signaling pathway in MDA-MB-231 cells. DETAILED DESCRIPTION
[0043] The following examples are only used to illustrate the present invention and should not be considered as limiting the scope of the present invention.
[0044] 1. Cell Experimental Research
[0045] Material
[0046] The human breast epithelial cancer cell line MDA-MB-231 was purchased from the Beina Bio-Cell Bank and cryopreserved in the Biochemical Pharmacology Laboratory of Bengbu Medical College. The compound of formula I and its salt (Jiangsu Hausen Pharmaceutical Co., Ltd.), DMEM high glucose medium (Hyclone), fetal bovine serum (Sijiqing), CCK-8 (Biosharp), Annexin V-FITC / PI kit (Bebo Bio), JC-1 detection kit, trypsin cell digestion solution, penicillin-streptomycin, RIPA lysis solution, PMSF, BCA protein concentration determination kit (Biyuntian), chloroquine (CQ) was purchased from Sigma, and β-actin, EGFR / p-EGFR, Akt / p-Akt, Caspase-3, PARP, LC3B antibodies were purchased from CST.
[0047] Cell culture
[0048] MDA-MB-231 cells were cultured in a medium containing 10% fetal bovine serum and 1×10 penicillin. 5 The cells were placed in a DMEM high-glucose medium containing 100 U / L and 100 mg / L streptomycin in a 37°C, 5% CO2 constant temperature incubator.
[0049] Example 1 Experimental study on cell viability
[0050] 1. Experimental methods
[0051] MDA-MB-231 cells were seeded in 96-well plates at 7×10 3 / well, placed in a constant temperature 37 ° C, 5% CO2 incubator, after the cells adhere to the wall, replace the culture medium in the well with a single compound of formula I (0, 1, 2, 4, 6, 8, 10, 12 μmol / L), 5 replicates per group, and set up a solvent control group. After continuing to culture in the incubator for 24, 48, and 72 hours, 10 μL of CCK-8 solution was added to each well, placed in the incubator for incubation for 2 hours, and the microplate reader was set at 450nm to detect the absorbance value (A) of each well at this wavelength. Repeat the experiment 3 times. Calculation formula: Cell survival rate (%) = (experimental group A / control group A) × 100%.
[0052] 2. Experimental results
[0053] The results of CCK-8 showed that the inhibitory effect of the compound of formula I on MDA-MB-231 cells gradually increased with the increase of drug concentration and time ( Figure 1 ), IC at 48 and 72h 50 The values were 2.777 μmol / L and 2.016 μmol / L respectively.
[0054] Example 2 Experimental study on cell proliferation inhibition
[0055] 1. Experimental methods
[0056] MDA-MB-231 cells were seeded in 6-well plates at 5×10 3 / well, after the cells adhered, the cell culture medium was replaced with fresh culture medium containing the compound of formula I (0, 0.4, 0.6, 0.8 μmol / L), and the cells were placed in an incubator. After 5 days, the culture medium was removed and washed twice with pre-cooled PBS, and then paraformaldehyde was added and placed at -20°C. After 10 minutes, crystal violet was added and placed at room temperature for 10 minutes, and then washed with double distilled water, dried at room temperature, and photographed. The experiment was repeated 3 times.
[0057] 2. Experimental results
[0058] The results of colony cloning experiments showed that ( Figure 2 ), the compound of formula I inhibited the formation of colonies in a dose-dependent manner.
[0059] Example 3 Cell morphology experimental study
[0060] 1. Experimental methods
[0061] MDA-MB-231 cells were seeded in 6-well plates at 2×10 5 / well, and when the cells are well attached to the wall in the incubator, the culture medium in the wells is discarded, and the cells are divided into four groups: Formula I compound (0, 4, 6, 8 μmol / L) group, and the cells are cultured for 24 hours and then photographed using an inverted microscope.
[0062] 2. Experimental results
[0063] The inverted microscope was used to observe that the morphology and density of cells in the group treated with the compound of formula I showed different degrees of changes compared with those in the control group. After treatment with 8 μmol / L compound of formula I, it was clearly seen that the cells atrophied more, the refractive index increased, and the number of suspended cells increased significantly ( Figure 3 ).
[0064] Example 4 Experimental study on cell apoptosis
[0065] 1. Experimental methods
[0066] MDA-MB-231 cells were seeded in 6-well plates at 2×10 5 / well, placed in an incubator, after the cells adhered, the culture medium was replaced with a culture medium containing the compound of formula I (0, 4, 6, 8 μmol / L), and the culture was continued for 24 h. The cells were collected using a centrifuge at 600 g, stained with Annexin-V-FITC / PI double staining reagent, and detected by flow cytometry. The experiment was repeated 3 times.
[0067] 2. Experimental results
[0068] Flow cytometry results showed that 8 μmol / L of compound I could significantly induce cell apoptosis (P<0.01, Figure 4 , Figure 5 ). Figure 6-7 The results of Western blot experiments showed that as the drug concentration increased, the expression of cleaved Caspase-3 gradually increased compared with the control group, and the PARP cleavage band in the group treated with 8 μmol / L Formula I compound increased significantly, and the difference was statistically significant (P<0.01).
[0069] Example 5 Experimental study on cell autophagy
[0070] 1. Experimental methods
[0071] MDA-MB-231 cells were seeded in a 60 mm dish, and when the cell density was appropriate and the cells adhered well to the wall, the compound of formula I (8 μmol / L) was added for 24 h, and the cells were collected at 600 g using a 4°C centrifuge, washed 3 times with PBS, fixed with 3% glutaraldehyde and 2% paraformaldehyde in 0.1 M PBS buffer (pH 7.4), and stored at 4°C. Finally, images were collected using a transmission electron microscope.
[0072] 2. Experimental results
[0073] Inverted microscope ( Figure 8 A) A large number of vacuoles were observed in the cells of the group given the compound of formula I (8 μmol / L). Figure 8B) Autophagic vesicles were observed in the cells of the drug group. Figure 9-10 Western blot results showed that the autophagy marker protein LC3B was cleaved in large quantities, and LC3B / Ⅱ increased in a dose-dependent manner.
[0074] Example 6 Effect of the autophagy inhibitor CQ on the sensitivity of the compound of formula I in treating triple-negative breast cancer.
[0075] 1. Experimental methods
[0076] (1) Cell survival rate experiment
[0077] MDA-MB-231 cells were seeded in 96-well plates at 7×10 3 / well, placed in a constant temperature 37 ° C, 5% CO2 incubator, after the cells adhere to the wall, the culture medium in the well is replaced with DMEM culture medium containing the compound of formula I (0, 1, 2, 4, 6, 8, 10, 12 μmol / L), CQ (40 μmol / L) and the compound of formula I (4, 6 μmol / L) combined with CQ, 5 replicates per group, and a solvent control group is set. After continuing to culture in the incubator for 24, 48, and 72 hours, 10 μL of CCK-8 solution is added to each well, placed in the incubator for incubation for 2 hours, and the microplate reader is set at 450nm to detect the absorbance value (A) of each well at this wavelength. Repeat the experiment 3 times. Calculation formula: Cell survival rate (%) = (experimental group A / control group A) × 100%.
[0078] (2) Western blot experiment
[0079] MDA-MB-231 cells were seeded in 60 mm dishes and treated with CQ (40 μmol / L) or compound of formula I (4 μmol / L) alone, or treated with CQ (40 μmol / L) and compound of formula I (4 μmol / L) together. The cells were treated with drugs for 24 h, and then the cells were collected and added with RIPA lysis buffer, lysed on ice for 30 min, centrifuged at 12 000 r / min at 4 ° C for 30 min, and the protein supernatant was extracted. The protein was quantified using the BCA method to make the protein concentration of each group equal. 30 μg protein was taken from each group, SDS-PAGE electrophoresis was performed, and then transferred to PVDF membrane, blocked with 5% skim milk for 4 h; the membrane was washed with TPBS 3 times, 5 min / time; incubated with primary antibody at 4 ° C overnight, and washed with TPBS 3 times; incubated with secondary antibody at room temperature for 2 h, and washed with TPBS 3 times; ECL kit luminescence development, and the image was obtained using a gel imaging system. Image J was used to measure the gray value of each colored band, and the ratio of the gray value of the target band to that of β-actin was used as the relative expression level of the target protein.
[0080] 2. Experimental results
[0081] After 1 hour of CQ pretreatment, CCK-8 assay showed that compared with the control group and the single-use compound of formula I (4, 6 μmol / L), the cell survival rate in the compound of formula I combined with CQ group was significantly reduced (P<0.01) ( Fig.11 ). It was also observed that in the group treated with compound I (4 μmol / L) combined with CQ, the expression of LC3B / Ⅱ was higher than that in the group treated with CQ alone and the group treated with compound I (4 μmol / L) alone, suggesting that CQ blocked cell autophagy and increased the accumulation of LC3B / Ⅱ ( Fig.12 and Fig.13 ).
[0082] Example 7 Study on the mechanism of the compound of formula I in treating triple-negative breast cancer
[0083] 1. Experimental methods
[0084] MDA-MB-231 cells were seeded in 60 mm dishes and treated with 0, 4, 6, and 8 μmol / L of the compound of formula I, respectively. After 24 hours of drug action, the cells were collected and added with RIPA lysis buffer, lysed on ice for 30 minutes, centrifuged at 12 000r / min at 4°C, and the protein supernatant was extracted. The protein was quantified using the BCA method to make the protein concentration of each group equal. 30 μg of protein was taken from each group, SDS-PAGE electrophoresis was performed, and then the membrane was transferred to a PVDF membrane, which was blocked with 5% skim milk for 4 hours; the membrane was washed with TPBS 3 times, 5 minutes / time; the primary antibody was incubated at 4°C overnight, and the membrane was washed with TPBS 3 times; the secondary antibody was incubated at room temperature for 2 hours, and the membrane was washed with TPBS 3 times; the ECL kit was used for luminescence development, and the image was obtained using a gel imaging system. Image J was used to determine the gray value of each color band, and the ratio of the gray value of the target band to that of β-actin was used as the relative expression of the target protein.
[0085] 2. Experimental results
[0086] Western blot analysis revealed that as the concentration of the compound of formula I increased, the expression of phosphorylated EGFR and AKT proteins in the cells gradually decreased, with significant differences compared with the control group (P<0.05). The results showed that the compound of formula I can inhibit the EGFR / PI3K / AKT signaling pathway ( Figure 14-16 ).
[0087] 2. Animal Model Experiment
[0088] In the nude mouse tumor model, the compound of formula I potently inhibited tumor growth of breast cancer cell lines. In the high-dose 20 mg / kg group, the compound of formula I or its pharmaceutically acceptable salt can almost completely regress the tumor.
[0089] Purpose:
[0090] In vivo efficacy experiments confirmed that the compound has a good therapeutic effect on breast cancer, especially triple-negative breast cancer.
[0091] Main instruments and materials for the experiment:
[0092] instrument:
[0093] 1. Biological safety cabinet (BSC-1300II A2, Shanghai Boxun Industrial Co., Ltd. Medical Equipment Factory)
[0094] 2. Clean bench (CJ-2F, Suzhou Fengshi Experimental Animal Equipment Co., Ltd.)
[0095] 3. CO2 incubator (Thermo-311)
[0096] 4. Centrifuge (Centrifuge 5702R, Eppendorf)
[0097] 5. Fully automatic cell counter (Countess II, Life)
[0098] 6. Pipette (10-20 μL, Eppendorf)
[0099] 7. Microscope (TS2, Nikon)
[0100] 8. Vernier caliper (CD-6" AX, Mitutoyo, Japan)
[0101] 9. Cell culture flask (T75 / T225, Corning)
[0102] 10. Electronic balance (CPA2202S, Sartorius)
[0103] Reagents:
[0104] 1. RPMI-1640 and DMEM culture medium (22400-089, Gibco)
[0105] 2. Fetal bovine serum (FBS) (10091-148, Gibco)
[0106] 3. 0.25% trypsin (25200-056, Gibco)
[0107] 4. Penicillin-streptomycin dual antibody (15140-122, Gibco)
[0108] 5. Phosphate buffered saline (PBS) (10010-023, Gibco)
[0109] 6. Matrigel Matrix (356234, Corning)
[0110] animal:
[0111] BALB / c nude mice, 6-8 weeks old, ♀, were purchased from Shanghai Xipu-Bikai Experimental Animal Co., Ltd.
[0112] Experimental procedures
[0113] Cell culture and cell suspension preparation
[0114] a. Take out breast cancer cells from the cell bank and resuscitate them. Place the resuscitated cells in a cell culture bottle (label the cell type, date, name of the culturer, etc. on the bottle wall) and culture them in a CO2 incubator (the incubator temperature is 37°C and the CO2 concentration is 5%).
[0115] b. After the cells have covered 80-90% of the bottom of the culture flask, they are subcultured and then placed in a CO2 incubator for further culture. This process is repeated until the number of cells meets the in vivo efficacy requirements.
[0116] c. Collect the cultured cells, count them using an automatic cell counter, and resuspend the cells with PBS and matrix gel according to the counting results to make a cell suspension (density 10×10 7 / mL) and placed in an ice box for later use.
[0117] Cell seeding
[0118] a. Before inoculation, nude mice were marked with disposable ear tags for both large and small mice.
[0119] b. Mix the cell suspension during inoculation, draw 0.1-1 mL of cell suspension with a 1 mL syringe, remove bubbles, and then place the syringe on an ice pack for later use.
[0120] c. Secure the nude mouse with your left hand, and disinfect the right side of the nude mouse's back near the right shoulder (inoculation site) with 75% alcohol. Start inoculation after 30 seconds.
[0121] d. The experimental nude mice were inoculated sequentially (0.1 mL of cell suspension was inoculated per mouse).
[0122] Tumor measurement, grouping and drug administration in tumor-bearing mice:
[0123] a. According to the tumor growth, the tumor was measured several days after inoculation and the tumor size was calculated. Tumor volume calculation: Tumor volume (mm 3 )=length(mm)×width(mm)×width(mm) / 2. When the tumor volume reaches a certain size, the mental state and eating habits of the nude mice are observed. When the nude mice are listless or eat less, a nude mouse can be randomly selected for dissection. The tumor, brain, heart, liver, kidney, bone tissue and lung tissue are sliced and stained with HE to observe tumor metastasis and progression, and confirm that the tumor-bearing mouse model is in the late stage or metastasis has occurred.
[0124] b, The mice were randomly divided into groups according to their weight and tumor size.
[0125] c. According to the grouping results, the test drug was started to be administered (administration method: oral administration; dosage: 5, 10, 20 mg / kg; administration volume: 10 mL / kg; administration frequency: once / day; administration cycle: 14 or 21 days; solvent: pH 4.1 acetic acid buffer).
[0126] d, Tumors were measured and weighed twice a week after the start of the test drug administration.
[0127] e, Animals were euthanized after the experiment.
[0128] f. Process the data using software such as Excel. Calculation of compound tumor inhibition rate TGI (%): When the tumor does not regress, TGI (%) = [(1-(average tumor volume at the end of a treatment group's administration - average tumor volume at the beginning of the treatment group's administration)) / (average tumor volume at the end of the solvent control group's treatment - average tumor volume at the beginning of the solvent control group's treatment)] × 100%. When the tumor regresses, TGI (%) = [1-(average tumor volume at the end of a treatment group's administration - average tumor volume at the beginning of the treatment group's administration) / average tumor volume at the beginning of the treatment group's administration] × 100%.
[0129] The results show that the compound can effectively inhibit the growth of breast cancer transplanted tumors in nude mice and cause the regression of transplanted tumors in nude mice, and the activity of the compound is dose-dependent.
[0130] 3. Clinical Trial Research
[0131] In an open, multicenter clinical trial to evaluate the once-daily oral administration of the mesylate salt of the compound of Formula I in patients with breast cancer, especially triple-negative breast cancer, patients in this study received a drug containing the mesylate salt of the compound of Formula I orally once daily to evaluate its safety, tolerability, pharmacokinetics (PK) and anti-tumor activity.
[0132] 1. The entire study consists of three stages:
[0133] (1) Dose escalation cohort (2) Dose expansion cohort and (3) Dose extension cohort.
[0134] 2. Subjects:
[0135] Patients eligible for dose escalation were 18 years of age or older and had histologically or cytologically confirmed breast cancer or triple-negative breast cancer.
[0136] 3. Duration of treatment:
[0137] One study treatment cycle was defined as 21 consecutive days of administration. Patients continued to receive treatment until disease progression or discontinuation criteria were met.
[0138] The results show that the clinical efficacy trend indicates that the product has good development value. The median survival time of breast cancer patients, especially triple-negative breast cancer patients, treated with the compound of formula I or its salt is significantly improved, the liver, lung and lymph node metastasis rates are significantly reduced, and the complete remission rate and partial remission rate are over 90%.
Claims
1. Use of a compound of formula I or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating breast cancer, in, The pharmaceutically acceptable salt is selected from one or a combination of the following: methanesulfonate, fumarate, maleate, acetate, hydrochloride, phosphate or sulfate; the breast cancer is triple-negative breast cancer; the triple-negative breast cancer is HER3+ or FISH-positive breast cancer.
2. The use according to claim 1, characterized in that The triple-negative breast cancer refers to cancer cells that are negative for estrogen receptor (ER) and progesterone receptor and produce a test result of 0, 1+ or 2+ when semi-quantitative immunohistochemical analysis is performed using a polyclonal anti-HER2 primary antibody.
3. The use according to claim 2, characterized in that: The cancer cells were FISH negative for HER2 gene amplification.
4. The use according to claim 1, characterized in that The triple-negative breast cancer is histopathologically characterized by a basal-like phenotype.
5. The use according to claim 1, characterized in that: The breast cancer is accompanied by mutations in one or more genes among BRCA1, BRCA2, PALB2, FANCM or TP53.
6. The use according to claims 1-5, characterized in that The breast cancer is advanced breast cancer with liver metastasis, lung metastasis, lymph node metastasis or bone metastasis.
7. The use according to claims 1-5, characterized in that Baseline plasma concentrations of sMET in breast cancer patients were greater than or equal to a median of 795 mg / mL.
8. The use according to claims 1-5, characterized in that The compound of formula I or a pharmaceutically acceptable salt thereof plays a role in treating breast cancer by inhibiting the EGFR / PI3K / AKT signaling pathway.
Citation Information
Patent Citations
EGFR inhibitor free base or acid salt polycrystalline form, preparation method therefor, and application
WO2017161937A1
